Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Enanta Pharmaceuticals Inc ENTA

Healthcare Biotechnology
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered... see more

Recent & Breaking News (NDAQ:ENTA)

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015

Business Wire February 8, 2016

Enanta Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference

Business Wire February 1, 2016

Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2015

Business Wire January 28, 2016

Enanta Pharmaceuticals Announces New R&D Initiatives in Hepatitis B Virus and Respiratory Syncytial Virus and Plan to Provide Data Updates on Programs in NASH and HCV at the 34th Annual J.P. Morgan Healthcare Conference

Business Wire January 11, 2016

Enanta Pharmaceuticals Announces That AbbVie Has Initiated Enrollment of Six Global Phase 3 Clinical Studies of Its Once-Daily, Pan-Genotypic Hepatitis C Treatment

Business Wire January 11, 2016

AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen

PR Newswire January 11, 2016

Enanta Pharmaceuticals Announces the U.S. FDA Grants Priority Review to AbbVie's Supplemental New Drug Application for VIEKIRA PAK® Without Ribavirin in Genotype 1B Chronic Hepatitis C Virus Patients with Compensated Cirrhosis

Business Wire January 7, 2016

U.S. FDA Grants Priority Review to AbbVie for Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Virus Patients with Compensated Cirrhosis

PR Newswire January 7, 2016

Enanta Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference Presentation to be Webcast on January 13, 2016 at 11:00 A.M. PT

Business Wire January 4, 2016

Enanta Pharmaceuticals Announces the Election of Bruce L.A. Carter, Ph.D. as Non-Executive Chairman of the Board of Directors

Business Wire December 14, 2015

Enanta Pharmaceuticals Announces FDA Acceptance of AbbVie's New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® for the Treatment of Genotype 1 Chronic Hepatitis C Virus Infection

Business Wire December 2, 2015

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2015

Business Wire November 23, 2015

Enanta Pharmaceuticals Announces Investigational Regimen Containing Enanta's Next-Generation Protease Inhibitor ABT-493 Demonstrates High Sustained Virologic Response Rates in Phase 2 Studies in Patients with Chronic Hepatitis C

Business Wire November 16, 2015

AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C

PR Newswire November 16, 2015

Enanta Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis

Business Wire November 14, 2015

Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2015

Business Wire November 13, 2015

Enanta Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference

Business Wire November 2, 2015

Enanta Pharmaceuticals Announces Data Presentations at The Liver Meeting® 2015

Business Wire October 1, 2015

Enanta Announces Approval of VIEKIRAX®(ombitasvir/paritaprevir/ritonavir tablets) in Japan for the Treatment of Genotype 1 Chronic Hepatitis C

Business Wire September 28, 2015

Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

Business Wire September 2, 2015